英文 |
1. Effects of barley intake on glycemic control in Japanese patients with type 2 diabetes
mellitus undergoing antidiabetic therapy: a prospective study. Osonoi T, Matsuoka T, Ofuchi K, Katoh M, Kobayashi T, Mochizuki K. Diabetol Int. 2021 Oct 20. doi.org/ 10.1007/s13340-021-00552-z.
2.
The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients
with Type 2 Diabetes Mellitus. Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Diabetes Ther. 2021 Sep;12(9):2499-2515.
3.
Associations between continuous glucose monitoring-derived metrics and diabetic
retinopathy and albuminuria in patients with type 2 diabetes. Wakasugi S, Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Nishida K, Shiraiwa T, Torimoto K, Kurozumi A, Gosho M, Shimomura I, Watada H. BMJ Open Diabetes Res Care. 2021 Apr;9(1):e001923. doi:10.1136/bmjdrc-2020-001923.
4.
AST-120 Treatment Alters the Gut Microbiota Composition and Suppresses Hepatic
Triglyceride Levels in Obese Mice. Hiraga Y, Kubota T, Katoh M, Horai Y, Suzuki H, Yamashita Y, Hirata R, Moroi M. Endocr Res. 2021 Nov;46(4):178-185.
5.
S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes
Mellitus Patients Treated with Dietary Therapy. Kondo S, Mochizuki K, Hariya N, Saito M, Doguchi S, Osonoi T. Drugs R D. 2021 Mar;21(1):91-101.
6.
Associations between continuous glucose monitoring-derived metrics and arterial
stiffness in Japanese patients with type 2 diabetes. Wakasugi S, Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Kuribayashi N, Taneda Y, Kojima Y, Gosho M, Shimomura I, Watada H. Cardiovasc Diabetol. 2021 Jan 7;20(1):15. doi: 10.1186/s12933-020-01194-2.
7.
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes:
prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial. Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Cardiovasc Diabetol. 2021 Jan 4;20(1):4. doi: 10.1186/s12933-020-01206-1.
8.
Effect of the FreeStyle Libre™ flash glucose monitoring system on glycemic control
in individuals with type 2 diabetes treated with basal-bolus insulin therapy: An open label, prospective, multicenter trial in Japan. Ogawa W, Hirota Y, Osonoi T, Tosaki T, Kato Y, Utsunomiya K, Nishimura R, Nakamura J. J Diabetes Investig. 2021 Jan;12(1):82-90. |
|---|
邦文 |
1.
当院に､おけるメトホルミンまたはSGLT2阻害薬効果不十分例でのSGLT2阻害薬またはメトホルミン
の切替/追加による短期的効果. 遅野井健，斎藤三代子，国府田尚矢，道口佐多子，大渕健介，加藤誠 診療と新薬 2021；58（8）：597-604.
2.
当院の2型糖尿病患者における2020年の患者プロファイルに関する検討
遅野井健，斎藤三代子，国府田尚矢，道口佐多子，大渕健介，加藤誠 診療と新薬 2021；58（5）：361-372.
3.
後期高齢2型糖尿病患者におけるα-グルコシダーゼ阻害薬へのDPP-4阻害薬の追加は腎機能低下を改善する.
遅野井健，斎藤三代子，国府田尚矢，道口佐多子，大渕健介，加藤誠 診療と新薬 2021；58（4）：317-324.
4.
逆流性食道炎合併2型糖尿病患者におけるプロトンポンプ阻害薬の適正使用に関する検討
遅野井健，斎藤三代子，国府田尚矢，道口佐多子，大渕健介，加藤誠 診療と新薬 2021；58（3）：183-189.
5.
2型糖尿病患者における週1回投与のGLP-1受容体作動薬セマグルチドの有効性および安全性の検討
遅野井健，斎藤三代子，国府田尚矢，道口佐多子，大渕健介，加藤誠 診療と新薬 2021；58（3）：190-198.
6.
2型糖尿病合併保存期慢性腎臓病患者における赤血球造血刺激因子製剤の腎保護効果
遅野井健，斎藤三代子，国府田尚矢，道口佐多子，大渕健介，加藤誠 診療と新薬 2021；58（2）：90-100. |
|---|